Magenta Therapeutics

December 06, 2018

Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting

Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.

November 21, 2018

Ash 2018 preview – smaller groups get their turn in the spotlight

Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.

July 02, 2018

June rush drives near-record quarter for biotech flotations

Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.

Magenta Therapeutics

Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting

Ash 2018 preview – smaller groups get their turn in the spotlight

June rush drives near-record quarter for biotech flotations

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Finding the next Vertex

Clinical setback lays bare Vertex’s weakness

SITC 2020 – embargo snafu triggers the first movers

Biopharma buyouts still pricey

More biotechs test the third way to market